E-6-O-p-coumaroyl scandoside methyl ester: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44584784 |
| CHEMBL ID | 506966 |
| MeSH ID | M0496482 |
| Synonym |
|---|
| CHEMBL506966 , |
| bdbm50305812 |
| e-6-o-p-coumaroyl scandoside methyl ester |
| 6-o-e-pcoumaroyl scandoside methyl ester |
| (e)-6-o-(p-coumaroyl)scandoside methyl ester |
| 83946-90-1 |
| AKOS040763621 |
| methyl (1s,4as,5r,7as)-7-(hydroxymethyl)-5-((3-(4-hydroxyphenyl)acryloyl)oxy)-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "A rapid and simple high-performance liquid chromatographic (HPLC) method has been developed for the determination of p-coumaric acid in rat plasma and applied to a pharmacokinetic study in rats after administration of a prodrug, E-6-O-p-coumaroyl scandoside methyl ester, isolated from Hedyotis diffusa (Willd." | ( Estimation of p-coumaric acid as metabolite of E-6-O-p-coumaroyl scandoside methyl ester in rat plasma by HPLC and its application to a pharmacokinetic study. Guo, X; Liu, K; Yan, L; Yao, G, 2006) | 0.77 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neutrophil elastase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0063 | 2.0734 | 22.3780 | AID453985 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protease binding | Neutrophil elastase | Homo sapiens (human) |
| transcription corepressor activity | Neutrophil elastase | Homo sapiens (human) |
| endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| serine-type endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| protein binding | Neutrophil elastase | Homo sapiens (human) |
| heparin binding | Neutrophil elastase | Homo sapiens (human) |
| peptidase activity | Neutrophil elastase | Homo sapiens (human) |
| cytokine binding | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| cytoplasm | Neutrophil elastase | Homo sapiens (human) |
| cytosol | Neutrophil elastase | Homo sapiens (human) |
| cell surface | Neutrophil elastase | Homo sapiens (human) |
| secretory granule | Neutrophil elastase | Homo sapiens (human) |
| azurophil granule lumen | Neutrophil elastase | Homo sapiens (human) |
| specific granule lumen | Neutrophil elastase | Homo sapiens (human) |
| phagocytic vesicle | Neutrophil elastase | Homo sapiens (human) |
| collagen-containing extracellular matrix | Neutrophil elastase | Homo sapiens (human) |
| extracellular exosome | Neutrophil elastase | Homo sapiens (human) |
| transcription repressor complex | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID453982 | Inhibition of human neutrophil elastase at 10 uM | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID358551 | Neuroprotective activity against glutamate-stimulated rat cortical cells assessed as cell viability at 0.1 uM after 1 hr by LDH assay relative to control | 2001 | Journal of natural products, Jan, Volume: 64, Issue:1 | Neuroprotective constituents from Hedyotis diffusa. |
| AID453981 | Inhibition of human neutrophil elastase at 3 uM | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID453985 | Inhibition of human neutrophil elastase | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID453984 | Inhibition of human neutrophil elastase at 100 uM | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID358553 | Neuroprotective activity against glutamate-stimulated rat cortical cells assessed as cell viability at 10 uM after 1 hr by LDH assay relative to control | 2001 | Journal of natural products, Jan, Volume: 64, Issue:1 | Neuroprotective constituents from Hedyotis diffusa. |
| AID453983 | Inhibition of human neutrophil elastase at 30 uM | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID453980 | Inhibition of human neutrophil elastase at 1 uM | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. |
| AID358552 | Neuroprotective activity against glutamate-stimulated rat cortical cells assessed as cell viability at 1 uM after 1 hr by LDH assay relative to control | 2001 | Journal of natural products, Jan, Volume: 64, Issue:1 | Neuroprotective constituents from Hedyotis diffusa. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||